Wuxi BiologicsPartnershipSwiss AB2 Bio inks US$ 686m license option...Nippon Shinyaku has secured an option to acquire exclusive US rights to commercialize AB2 Bio’s tadekinig alfa to treat primary monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 … more ➔
Project EadenMeat alternativesProject Eaden bags €15m to scale up prod...Berlin-based food tech start-up Project Eaden is prepared to launch its first plant-based ham product by mid-year in 2,000 REWE supermarkets. A oversubscribes Series A financing laid the basis for this … more ➔
Adobe Stock - whitehoune FinancingCeres Brain Therapeutics announces €6m f...Paris-based drug delivery specialist Ceres Brain Therapeutics SA has raised €6m led by ANJAC, a French family-owned industrial group and preferred partner of healthcare laboratories and beauty and … more ➔
Arctic TherapeuticsFinancingArctic Therapeutics ASA kicks off with €...Iceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases … more ➔
EU ParliamentBiologisation of industryEuropaBio calling for EU Biotech ActEuropaBio calls for an ambitious cross-sectoral EU Biotech Act, that strengthens Europe as a global biotechnology leader for competitiveness and strategic autonomy. more ➔
adobe stock.com - HomuGallery EMAPRAC: Semaglutide linked to rare eye disea...The Safety Committee PRAC of the European Medicines Agency EMA is investigating a new potential adverse reaction to the appetite suppressant semaglutide. Epidemiological studies indicate that the rare … more ➔
InflaRx Acute Respiratory Distress SyndromeInflaRx secures European Commission approv...Jena-based InflaRx has reached a significant milestone with the European Commission’s approval of GOHIBIC (Vilobelimab), a novel anti-C5a monoclonal antibody for the treatment of SARS-CoV-2-induced … more ➔
David_SMC from PixabayInfectious diseaseSynairgen raises £18m for Phase 2 INVENT...Synairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. The funding will advance the Phase 2 INVENT trial, assessing SNG001, … more ➔
By Vaccinationist - PubChem, WikipediaIntra-CellularJohnson & Johnson acquires Intra-Cell...Johnson & Johnson has announced the acquisition of biopharmaceutical company Intra-Cellular Therapies, strengthening its position in the market for central nervous system disorder treatments. The $14.6 … more ➔
robin_24, WikipediaLeyden LabsLeyden Labs secures $70M to advance intran...Leyden Labs has raised $70 million in a funding round led by ClavystBio and Polaris Partners, boosting its efforts to develop intranasal antibody therapies targeting respiratory viruses, including influenza … more ➔
Wuxi Biologics
Project Eaden
Adobe Stock - whitehoune 
Arctic Therapeutics
EU Parliament
adobe stock.com - HomuGallery 
InflaRx 
David_SMC from Pixabay
By Vaccinationist - PubChem, Wikipedia
robin_24, Wikipedia